Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2014-01-08

Last Posted Date: 2019-05-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 721

Registration Number: NCT02030600

Locations: 🇵🇷
Novo Nordisk Investigational Site, San Juan, Puerto Rico

Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo
Drug: metformin
Drug: warfarin

First Posted Date: 2013-12-27

Last Posted Date: 2017-04-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02022254

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2
Healthy

Interventions: Drug: semaglutide

First Posted Date: 2013-12-20

Last Posted Date: 2018-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT02016911

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Phase 1

Completed

Conditions: Diabetes
Healthy
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide

First Posted Date: 2013-12-18

Last Posted Date: 2018-04-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 71

Registration Number: NCT02014259

Locations: 🇭🇺
Novo Nordisk Investigational Site, Budapest, Hungary

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: sitagliptin

First Posted Date: 2013-12-11

Last Posted Date: 2017-03-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 368

Registration Number: NCT02008682

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, China

Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Other: No treatment given

First Posted Date: 2013-12-09

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 98

Registration Number: NCT02005198

Locations: 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2013-12-06

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 67

Registration Number: NCT02003677

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2013-12-03

Last Posted Date: 2017-10-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 37

Registration Number: NCT01999322

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2013-11-25

Last Posted Date: 2016-11-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 48

Registration Number: NCT01992588

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia

Completed

Conditions: Haemophilia B With Inhibitors
Haemophilia A With Inhibitors
Haemophilia B
Congenital Bleeding Disorder
Haemophilia A

Interventions: Other: No treatment given

First Posted Date: 2013-11-20

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 381

Registration Number: NCT01988532

Locations: 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy